Adenocarcinoma of the Endometrium: An Institutional Review

Size: px
Start display at page:

Download "Adenocarcinoma of the Endometrium: An Institutional Review"

Transcription

1 Pieter Baltens, Feast of St. George. From the collection of Dr. Gordon and Adele Gilbert of St. Petersburg, Florida. Adenocarcinoma of the Endometrium: An Institutional Review Denis Cavanagh, MD; James V. Fiorica, MD; Mitchel S. Hoffman, MD; John Durfee, MD; and Santo V. Nicosia, MD The pathology, diagnosis, and management of endometrial cancer are reviewed. Background: Many oncologists regard endometrial cancer as a relatively benign and easily treatable gynecologic tumor. Inadequate care can result in poor outcomes. Methods: The authors review the epidemiology and pathology of the disease, and they compare disease characteristics and outcomes of FIGO staging with their own 11- year experience at a tertiary referral center. Results: Patients referred to tertiary referral centers tend to present with more advanced stages of disease than those reported by FIGO, although the profile of histologic types is similar. Conclusions: Prevention and early detection of endometrial cancer can minimize the impact of this disease. Complete staging and tumor removal including extrafascial hysterectomy with bilateral salpingo-oophorectomy, pelvic lymphadenectomy, and selective paraaortic lymphadenectomy are the cornerstones of surgical therapy. Introduction Adenocarcinoma of the endometrium ranks fourth in incidence among invasive tumors in women, following breast, lung, and colon cancers. In 1999, approximately 6,000 deaths will be caused by adenocarcinoma of the endometrium, and 35,000 new cases of this disease will be diagnosed. 1 This death-to-diagnosis ratio of approximately 1 to 6 indicates a generally favorable prognosis. However, a prior American Cancer Society and SEER projection for 1986 indicated a death-to-diagnosis ratio of 1 to 12, so there is increasing concern about the virulence of this disease. 2 For this reason, physicians and nurses should be aware of the epidemiological profile of the patient with adenocarcinoma of the endometrium and its precursors, the best methods of early detection, and the factors that influence the management of the individual patient. Epidemiology Adenocarcinoma of the endometrium is typically a disease of postmenopausal women with approximately 85% of the patients being over 50 years of age. With longer life expectancy for American women, the disease is becoming increasingly important. Menopause after age 52, nulliparity, obesity, diabetes, previous radiation, and the administration of unopposed estrogen and tamoxifen are the main factors that predispose to this type of cancer. Patient Experience During the 11-year period between 1987 and 1997, 290 patients with endometrial cancer were treated at our institution. A review of our experience with this group highlights key areas relating to diagnosis, pathology, management, and outcomes. The modal age was 60 to 69 years, with only 43 (15%) of the 290 patients being under 40 years of age (Fig 1). The distribution of histologic subtypes of tumor is summarized in Table 1. The distribution of cases by stage is shown in Table 2. The greater proportion of patients with more advanced stages in our series in comparison to data from the International Federation of Gynecology and Obstetrics (FIGO) reflects the referral pattern to our institution. Fifty-one percent of our patients were treated with surgery only, 20% received surgery plus radiation, 10% had surgery and chemotherapy, 4% had surgery plus hormones, 2% were treated with radiation alone, and 13% received other therapy. Fig 1. Age at diagnosis of 290 patients with endometrial cancer seen at Moffitt Cancer Center ( ). Table 1. Endometrial Carcinoma: Histopathologic Subtypes Encountered at the

2 H. Lee Moffitt Cancer Center ( ) Number of Patients Percentage Adenocarcinoma (endometrioid) Adenocarcinoma (papillary serous) Carcinoma (adenosquamous) Adenocarcinoma (with squamous metaplasia) Adenocarcinoma (clear cell) Carcinoma (undifferentiated type) Total 290 Table 2. Distribution of Cases of Endometrial Carcinoma by Stage Stage FIGO Report 1994* Moffitt Series I 9,692 (70.0%) %) II 1,885 (13.6%) 35 (12.1%) III 1,303 (9.4%) 45 (15.5%) IV 459 (3.3%) 35 (12.1%) Unknown or unstaged 499 (3.6%) 3 (1.0%) Total 13, *Adapted from Pettersson. 19 The majority of patients (87%) experienced no recurrence. Distant, local, and regional recurrences were seen in 7%, 0.7%, and 2% of patients, respectively. Eight patients (2.4%) were never disease-free. Table 3 summarizes the survival experience from our institution and compares it with pooled FIGO data. Table 3. Actuarial Percentage 5-Year Survival Data for Carcinoma of the Endometrium by Stage Stage FIGO 1994* Moffitt Series I II III IV Overall * FIGO stage I-IV overall actuarial 5-year survival varied from 66% in Slovakia to 86% in Spain with an average of 74% from reporting institutions in the United States. **Adapted from Pettersson. 19 Pathology Precursors of Endometrial Carcinoma A range of hyperplastic lesions of the endometrium has long been recognized often in association with frank malignancy or in women considered at high risk for endometrial carcinoma. In 1900, Cullen 3 suggested an etiologic relationship between endometrial hyperplasia and cancer, and reviews by Taylor 4 and Novak and Yui 5 supported this view. In 1947, Gusberg 6 labeled the entire spectrum of hyperplastic lesions adenomatous hyperplasia, drew attention to their production by both endogenous and exogenous estrogenic stimulation, and emphasized their role as precursors of frank carcinoma. The first complete classification of endometrial hyperplasia was that of Hertig and Sommers 7 published in Subsequent to these early studies, numerous authors have attempted to classify endometrial hyperplasias, but unfortunately, the results have been in a range of descriptive terminology, diagnostic labels, and treatment plans that "have conspired to confuse both the pathologist (in the formulation of meaningful diagnosis) and the gynecologist (in therapeutic decision making)." 8 In 1974, Vellios 9 commented that the so-called "hyperplasias" of the endometrium would be more appropriately termed "dysplasias" in a manner analogous to lesions of the cervix. This led us to review the work of Richart 10 on the classification of the precursors of invasive cervical carcinoma. He developed the unifying concept of cervical intraepithelial neoplasia (CIN) to replace the profusion of terms describing the precursors of invasive cervical cancer. Ruffolo et al 11 proposed a similar classification for the precursors of endometrial carcinoma, labeling them GIN-I, GIN-II and GIN-III to signify glandular intraepithelial neoplasia, grades I, II, and III. GIN-I includes cystic hyperplasia and adenomatous hyperplasia without atypia (Fig 2). GIN-II includes adenomatous hyperplasia of moderate degree and atypical hyperplasia (Fig 3), and GIN-III includes severe atypical hyperplasia as described by Vellios 12 and carcinoma in situ, as described by Hertig and Sommers 7 (Fig 4). No classification is generally accepted, but whichever one is used, the presence or absence of atypia should be recognized because this parameter best reflects the subsequent cancer risk.

3 Fig 2. GIN-I. Cystic dilation of the glands branches to form additional small glands (hematoxylin-eosin stain). Fig 3. GIN-II. The glands appear more crowded and are rather large. Normal stroma separates the glands (hematoxylin-eosin stain). Fig 4. GIN-III. The glands appear crowded, some being "back to back" but separated by delicate fibers of endometrial stroma. Even at this magnification, the glandular epithelium has a disorganized appearance (hematoxylin-eosin stain). Histopathology of Endometrial Carcinoma Carcinoma of the endometrium occurs in a number of subtypes, each varying in its propensity to create myometrial invasion and metastases. The relative frequencies of the various subtypes varies with time and from one institution to another. Table l shows the subtypes in our series. Adenocarcinoma Adenocarcinoma of endometrioid type is estrogen-dependent. It is the most common variety and accounts for approximately three fourths of patients in this series. Histopathologically, it is characterized by the proliferation of abnormal glands in an abnormal relationship to one another. Little or no stroma separates the glands. The lining epithelium may be infolded or slightly papillary. The cells are enlarged with variable numbers of mitotic figures. In accordance with the FIGO system established in 1988, three grades of adenocarcinoma are recognized: grade I is well differentiated (Fig 5), grade II is moderately differentiated with partly solid areas (Fig 6), and grade III is predominantly solid or entirely undifferentiated (Fig 7). Fig 5. FIGO grade I endometrial carcinoma. Fig 6. FIGO grade II endometrial Well-differentiated endometrial cells from glandular adenocarcinoma. The tumor consists of moderately structures are seen, which are cribriform in this case. well-differentiated malignant glands, with areas of There are no solid masses of tumor cells solid tumor interspersed with glandular tumor (hematoxylin-eosin stain). elements (hematoxylin-eosin stain). Fig 7. FIGO grade III adenocarcinoma of the endometrium. The tumor consists of solid sheets of malignant cells with no attempt to form glandular structures (hematoxylin-eosin stain). Papillary Serous Carcinoma This tumor, which was present in 45 (16%) of our patients, has a poor prognosis. It is distinguished from clear cell carcinoma by the absence of a clear cell component. Its appearance is suggestive of ovarian carcinoma, and the tumor cells are supported on thin, fibrovascular cores forming delicate papillary fronds (Fig 8). Fig 8. Papillary serous adenocarcinoma. The tumor cells are supported on fibrovascular cores forming delicate papillary fronds (hematoxylineosin stain). Adenocarcinoma With Squamous Differentiation The first type of this neoplasm, formerly called adenoacanthoma, was present in only l (0.3%) of our 290 patients. It is an adenocarcinoma with areas of benign squamous epithelium that are usually scattered throughout the tumor but occasionally are localized (Fig 9). The second type, formerly called adenosquamous carcinoma, was found in 14 (5%) of our patients. This is characterized by the presence of both malignant glandular and malignant squamous elements (Fig 10). Adenosquamous carcinoma has a worse prognosis than adenoacanthoma.

4 IIA G123 Endocervical glandular involvement only Fig 9. Well-differentiated adenocarcinoma with foci of benign squamous metaplasia. It is important to differentiate between this tumor and adenosquamous carcinoma, which has a much poorer prognosis (hematoxylin-eosin stain). Fig 10. Adenosquamous carcinoma. The tumor includes malignant glandular components and squamous elements (hematoxylin-eosin stain). Clear Cell Adenocarcinoma This tumor was present in 9 (3%) of our patients. It consists of polygonal, hobnail-shaped, or flattened cells arranged in solid masses or in tubular, papillary, or cystic patterns (Fig 11). Fig 11. Clear cell adenocarcinoma. In this field, tumor cells form solid sheets. Prominent distally placed nuclei create a hobnail appearance. The histologic appearance of this tumor is identical regardless of where it arises in the Müllerian system endometrium, ovary, or cervix (hematoxylineosin stain). Undifferentiated Carcinoma This type, which was present in only 1 of our patients, carries a poor prognosis. Secretory Adenocarcinoma This tumor is characterized by a glandular pattern with cells forming uniform, subnuclear vacuolization similar to that seen in the luteal phase of the menstrual cycle. Diagnosis Postmenopausal bleeding should always be thoroughly investigated with cognizance that the Papanicolaou smear is positive in a minority of patients with adenocarcinoma of the endometrium (Fig 12). Women should be cautioned to contact their physician if postmenopausal bleeding occurs so that an adequate investigation can be undertaken. An endometrial biopsy will give the diagnosis in approximately 90% of patients. The Pipelle endometrial biopsy (Unimar Co, Wilton, Conn) provides excellent specimens. These devices should be used in conjunction with endocervical curettage to ensure that an endocervical lesion is not overlooked. If these biopsies are negative but the patient continues with perimenopausal or postmenopausal bleeding, then a fractional curettage of the uterus (endometrium and endocervix) is performed under general anesthesia. Hysteroscopy may be useful but should always be combined with fractional curettage to reduce diagnostic failure to a minimum. 13 Ultrasound is as useful as magnetic resonance imaging in estimating the thickness of the endometrial stripe (over 8 mm is significant) and depth of invasion preoperatively, and it also is less expensive. Endometrial hyperplasia usually can be treated with progestational agents such as 20 mg of megestrol acetate given daily. The patients should be followed with endometrial biopsy and/or dilation and curettage every 6 months. Progression to severe atypia or cancer calls for hysterectomy. Fig 12. A Papanicolaou smear showing a cohesive group of malignant glandular endometrial cells shed from a well-differentiated adenocarcinoma. Individual cells display micronucleoli and focal squamous metaplasia. Pap smears are positive in a minority of cases of endometrial carcinoma (hematoxylin-eosin stain). Management Treatment for adenocarcinoma of the endometrium depends on the FIGO stage (Table 4). The surgical keystone is total extrafascial abdominal hysterectomy with bilateral salpingo-oophorectomy For accurate surgical staging, pelvic and periaortic lymphadenectomy is performed. It is well recognized that node dissection is prognostically valuable, 14 and Kilgore et al 15 demonstrated that patients with endometrial cancer who underwent multiple-site pelvic node sampling had better survival than those who did not (P=0.0002). When patients were classified as low-risk disease (corpus only) or high-risk disease (involving cervix, adnexa, uterine serosa, or positive washings), multiple-site nodal sampling again provided a significant advantage in survival compared with patients without node sampling (high risk P=0.0006, low risk P=0.026). Also, patients who received whole pelvic radiation for grade III lesions or who had deep myometrial invasion had better survival rates after multiple site pelvic node sampling than those in whom nodes were not sampled (P=0.0027). This survival advantage for patients having multiple site node sampling overall and for patients in high- and low-risk groups strongly suggests a therapeutic benefit. Adjuvant chemotherapy, hormonal therapy, or chemoradiotherapy may be logically directed in these high-risk patients, which comprised 40% of our cases (Table 2). Table 4. FIGO Corpus Cancer Staging (1988) IA G123 IB G123 IC G123 Tumor limited to endometrium Invasion to <1/2 myometrium Invasion to >2 myometrium

5 IIB G123 IIIA G123 IIIB G123 IIIC G123 Cervical stromal invasion Tumor invades serosa and/or adnexa and/or positive cytology Vaginal metastases Metastases to pelvic and/or paraaortic lymph nodes IVA G123 IVB G123 Tumor invasion bladder and/or bowel mucosa Distant metastases including intraabdominal and/or inguinal lymph nodes From Pettersson F, ed. FIGO Annual Report on the Results of Treatment in Gynecologic Cancer: Cancer of the Corpus Uteri. Stockholm, Sweden: International Federation of Gynecology and Obstetrics; 1995: Reprinted with permission. Many gynecologists are confident that they can treat patients with stage 1 endometrial carcinoma adequately. However, because few are capable of performing an adequate pelvic lymphadenectomy, patients are not being accurately staged according to the 1988 FIGO criteria. Thus many patients with stage 1 disease are being understaged. The patient should be referred to a gynecologic oncologist for treatment if the tumor stage is advanced or the tumor is poorly differentiated or if a high-risk histopathologic lesion such as a serous papillary, clear cell, or secretory carcinoma is detected at fractional curettage. Cases with cervical stromal involvement (stage IIB), if recognized, should also be referred because more extensive surgery involving radical hysterectomy, pelvic lymphadenectomy, and selective paraaortic lymphadenectomy will be required. During the operation, peritoneal washings are collected for cytology and the uterus is evaluated by frozen section to assess tumor type, grade and depth of invasion. Estrogen- and progesterone-receptor status should be evaluated to provide additional information on the permanent sections. Nodal metastases are often associated with other high-risk features such as lymphatic or vascular involvement. These factors are used to better assess prognosis and to assist in decisions regarding adjuvant treatments. At our center, only approximately 50% of our patients were treatable by surgery alone. All of these patients had an extrafascial abdominal hysterectomy and pelvic and periaortic selective node dissections unless contraindicated by such conditions as morbid obesity. Decisions regarding radiotherapy should follow complete surgical staging of the lesion in accordance with the 1988 FIGO staging classification. Preoperative radiotherapy is now rarely justified. If postoperative radiotherapy is to be given, a vaginal applicator should be used rather than external therapy in selected stage I patients. A vaginal applicator appears to provide a better therapeutic index, especially when the extrafascial hysterectomy with bilateral salpingo oophorectomy is accompanied by an extensive pelvic and periaortic lymphadenectomy. 16 This treatment is also less expensive than the external-beam approach. Recurrence Recurrence of endometrial carcinoma is most common in the high-risk cases and in premenopausal or younger (under 45 years) women. The incidence of ovarian metastases at presentation is approximately 30% for younger women compared with approximately 5% in women over 45 years of age. 17 Since approximately 85% of recurrences occur within the first three years of treatment, 18 patients are followed every two to three months for the first three years after treatment and thereafter at six-month intervals. The cornerstones of adequate follow-up are investigation of any history of vaginal bleeding, careful pelvic examination with a Papanicolaou smear at each visit, and annual chest radiograph and mammogram. An elevated serum CA-125 level of over 35 U/mL may be the first sign of recurrence in a patient with a stenosed upper vagina following radiotherapy because in these cases, vaginal bleeding is unlikely and pelvic examination is unsatisfactory. Routine computed tomography scans are not generally necessary but are considered if the clinical situation suggests recurrence. Fine-needle aspiration can confirm recurrence. Magnetic resonance imaging is expensive and rarely helpful in this situation. Local recurrences are usually at the vault of the vagina and/or in the suburethral area. Localized recurrences in patients who have not received previous radiotherapy may be treated with radiotherapy. Metastases to bone can be treated with localized radiotherapy, which is highly effective in relieving pain. For pulmonary metastases, hormonal therapy with 80 to 320 mg/day of megestrol acetate (Megace) or 20 to 40 mg/day of tamoxifen should be tried. A complete response rate of approximately 20% has been reported with hormonal therapy. Hormonal therapy is probably most effective when the tumor tissues contain receptors. The value of 80 mg of megestrol acetate twice daily for three weeks, alternating with 20 mg of tamoxifen twice daily for three weeks, is being investigated in the Gynecologic Oncology Group protocol 153. In cases where levels are low, chemotherapy should be considered. If chemotherapy is to be used, it should be carried out by a gynecologic oncologist or a medical oncologist. Discussion Our overall survival results are slightly inferior to FIGO rates. This is partly explained by the fact that only 60% of our patients had stage I disease compared with 73% in the FIGO report. In addition, 24.5% of our patients were in the poor histopathologic prognosis categories (eg, papillary serous, adenosquamous, clear cell, and undifferentiated carcinomas). This also explains why only approximately 50% of our patients were treated with surgery alone. Despite frequent warnings over many years, carcinoma of the endometrium remains an underrated tumor. Its management is often performed more casually than its virulence may warrant. That it is overall the least aggressive of gynecologic malignancies should not obscure the fact that for many women, this tumor is a cause of considerable morbidity from surgery and from radiation and chemotherapy used to supplement surgical treatment. Also, many patients who have what is generally assumed to be an easily curable, "early-stage" carcinoma die of the disease because gynecologic oncologists are not generally available to manage and accurately stage them. Conclusions The optimal treatment of early-stage endometrial carcinoma is still not fully defined. Known and as yet unrecognized prognostic factors must be sought by clinical and laboratory methods. New methods of therapy for extensive disseminated or recurrent disease must be carefully evaluated. All women with this cancer should have the benefit of consultation with a gynecologic oncologist before treatment begins. However, the key to reducing the mortality and morbidity of this disease is improved patient and physician education, which will result in earlier diagnosis and treatment. References 1. Cancer Facts and Figures, Atlanta, Ga: The American Cancer Society; Cancer Facts and Figures, Atlanta, Ga: The American Cancer Society; Cullen TS. Cancer of the Uterus: Its Pathology, Symptomatology, Diagnosis and Treatment. New York, NY: D Appleton and Co; Taylor HC. Endometrial hyperplasia and carcinoma of the body of the uterus. Am J Obstet Gynecol. 1932;23: Novak E, Yui E. Relationship of endometrial hyperplasia to adenocarcinoma of the uterus. Am J Obstet Gynecol. 1936;32: Gusberg SB. Precursors of corpus carcinoma: estrogens and adenomatous hyperplasia. Am J Obstet Gynecol. 1947;54: Hertig AT, Sommers SC. Genesis of endometrial carcinoma. I. Study of prior biopsies. Cancer. 1949;2: Scully RE. Definition of endometrial carcinoma precursors. Clin Obstet Gynecol. 1982;25: Vellios F. Endometrial hyperplasia and carcinoma in situ. Gynecol Oncol. 1974;2:

6 10. Richart RM. Cervical intraepithelial neoplasia. In: Pathology Annual. New York, NY: Appleton-Century-Crofts; 1973: Ruffolo EH, Cavanagh D, Marsden DE. Glandular intraepithelial neoplasia (GIN): a unifying concept of the precursors of endometrial carcinoma. Aust N Z J Obstet Gynaecol. 1983;23: Vellios L. Endometrial hyperplasia, precursor of endometrial carcinoma. In: Sommers SC, ed. Pathology Annual. New York, NY: Appleton-Century-Crofts; 1972: Marsden DE, Correy JF. An evaluation of hysteroscopy in clinical gynaecologic practice. Asia-Oceana J Obstet Gynaecol. 1981;7: Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 1987;60: Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 1995;56: Orr JW Jr, Holiman JL, Orr PF. Stage I corpus cancer: is teletherapy necessary. Am J Obstet Gynecol. 1997;176: Gitsch G, Hanzal E, Jensen D, et al. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol. 1995;85: Berchuck A. Endometrial carcinoma and its precursors. Curr Ther Endocrinol Metab. 1997;6: Pettersson F, ed. FIGO Annual Report on the Results of Treatment in Gynecologic Cancer: Cancer of the Corpus Uteri 13,040 Patients Treated Stockholm, Sweden: 1994;22; From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the University of South Florida College of Medicine, Tampa, Fla. Address reprint requests to Denis Cavanagh, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida College of Medicine, 4 Columbia Dr, Ste 529, Tampa, FL No significant relationship exists between the authors and the companies/organizations whose products or services may be referenced in this article. Dr Fiorica is on the Speakers Bureau for Bristol-Myers Squibb Co. Back to Cancer Control Journal Volume 6 Number 4

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%

More information

One of the commonest gynecological cancers,especially in white Americans.

One of the commonest gynecological cancers,especially in white Americans. Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in

More information

Endometrial Cancer. Incidence. Types 3/25/2019

Endometrial Cancer. Incidence. Types 3/25/2019 Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy

More information

Staging and Treatment Update for Gynecologic Malignancies

Staging and Treatment Update for Gynecologic Malignancies Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths

More information

Page # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases:

Page # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases: Endometrium Pathology of the Endometrium Thomas C. Wright Columbia University, New York, NY Most common diseases: Abnormal uterine bleeding Inflammatory conditions Benign neoplasms Endometrial cancer Anatomical

More information

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs

More information

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

Adjuvant Therapies in Endometrial Cancer. Emma Hudson Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial

More information

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?

More information

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion 5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

receive adjuvant chemotherapy

receive adjuvant chemotherapy Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer

More information

What is endometrial cancer?

What is endometrial cancer? Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women

More information

Index. B Bilateral salpingo-oophorectomy (BSO), 69

Index. B Bilateral salpingo-oophorectomy (BSO), 69 A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell

More information

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT

More information

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas) CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging

More information

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

Gynecologic Malignancies. Kristen D Starbuck 4/20/18 Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial

More information

Cervical Cancer: 2018 FIGO Staging

Cervical Cancer: 2018 FIGO Staging Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford

More information

2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA

2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA 2009 USCAP Gyn Pathology Evening Session Case #3 Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA rzaino@psu.edu Clinical history Middle aged woman with an exophytic mass of

More information

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES PHYSICAL EXAMINATION CASE 1: FEMALE REPRODUCTIVE 3/5 Patient presents through the emergency room with

More information

Endometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines

Endometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology

More information

Cervical cancer presentation

Cervical cancer presentation Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000

More information

ARRO Case: Early-stage Endometrial Cancer

ARRO Case: Early-stage Endometrial Cancer ARRO Case: Early-stage Endometrial Cancer Ankit Modh, MD (PGY-4) Faculty Advisor: Mohamed A Elshaikh, MD Department of Radiation Oncology Henry Ford Cancer Institute Case Presentation 70 y/o African American

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND

More information

Atypical Hyperplasia/EIN

Atypical Hyperplasia/EIN EIN Atypical Hyperplasia/EIN Based on scientific and diagnostic advances, in 2014 the WHO moved that the precursor lesion for endometrioid carcinoma be atypical hyperplasia/ein, rather than what was previously

More information

bleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the

bleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis

More information

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with

More information

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology bs_bs_banner doi:10.1111/jog.12596 J. Obstet. Gynaecol. Res. Vol. 41, No. 2: 167 177, February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology

More information

This protocol is intended to assist pathologists in providing

This protocol is intended to assist pathologists in providing Protocol for the Examination of Specimens From Patients With Carcinomas of the Endometrium A Basis for Checklists Steven G. Silverberg, MD, for the Members of the Cancer Committee, College of American

More information

ENDOMETRIAL CANCER: A GUIDE FOR PATIENTS

ENDOMETRIAL CANCER: A GUIDE FOR PATIENTS ENDOMETRIAL CANCER: A GUIDE FOR PATIENTS PATIENT INFORMATION BASED ON ESMO CLINICAL PRACTICE GUIDELINES This guide for patients has been prepared by Reliable Cancer Therapies (RCT) as a service to patients,

More information

NAACCR Webinar Series /7/17

NAACCR Webinar Series /7/17 COLLECTING CANCER DATA: UTERUS 2017 2018 NAACCR WEBINAR SERIES Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013

Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke

More information

Vaginal intraepithelial neoplasia

Vaginal intraepithelial neoplasia Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the

More information

Management of Endometrial Hyperplasia

Management of Endometrial Hyperplasia Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New

More information

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on? MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion

More information

ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)

ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic

More information

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas) C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2

More information

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix. Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying

More information

The new FIGO classification in endometrial carcinoma

The new FIGO classification in endometrial carcinoma The new FIGO classification in endometrial carcinoma Poster No.: C-1073 Congress: ECR 2012 Type: Educational Exhibit Authors: A. IGLESIAS CASTAÑON, M. Arias Gonzales, J. Mañas Uxó, 1 2 1 2 2 2 B. NIETO

More information

Algorithms for management of Cervical cancer

Algorithms for management of Cervical cancer Algithms f management of Cervical cancer Algithms f management of cervical cancer are based on existing protocols and guidelines within the ESGO comunity and prepared by ESGO Educational Committe as a

More information

ENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media

ENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media For mass reproduction, content licensing and permissions contact Dowden Health Media. UPDATE ENDOMETRIAL CANCER Are lymphadenectomy and external-beam radiotherapy valuable in women who have an endometrial

More information

Uterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!!

Uterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!! Uterine October 7, 2010 NAACCR 2010-2011 Webinar Series Session 1 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes!!! 3 NAACCR 2010-2011 Webinar

More information

UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS

UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS Review Journal of Translational Medicine and Research, volume 19, no. 1-2, 2014 UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS N. Bacalbaæa 1, A. Traistaru 2, I. Bãlescu 3 1 Carol Davila University of Medicine

More information

ARROCase: Locally Advanced Endometrial Cancer

ARROCase: Locally Advanced Endometrial Cancer ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal

More information

Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY

Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY SCIENTIFIC COORDINATOR: PROF. DR. MIHAI B. BRĂILA, Ph.D. Ph.D. Graduand:

More information

Endometrium. Protocol applies to all carcinomas of the endometrium. Procedures Cytology (No Accompanying Checklist) Biopsy Curettage Hysterectomy

Endometrium. Protocol applies to all carcinomas of the endometrium. Procedures Cytology (No Accompanying Checklist) Biopsy Curettage Hysterectomy Endometrium Protocol applies to all carcinomas of the endometrium. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying

More information

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru Sarah Burton Lead Gynae Oncology Nurse Specialist Cancer Care Cymru Gynaecological Cancers Cervical Cancers Risk factors Presentation Early sexual activity Multiple sexual partners Smoking Human Papiloma

More information

Summary CHAPTER 1. Introduction

Summary CHAPTER 1. Introduction Summary This thesis aims to evaluate the diagnostic work-up in postmenopausal women presenting with abnormal vaginal bleeding. The Society of Dutch Obstetrics and Gynaecology composed a guideline, which

More information

Impact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma

Impact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma Hou et al. / Cancer Cell Research 3 (2014) 65-69 Cancer Cell Research Available at http:// http://www.cancercellresearch.org/ ISSN 2161-2609 Impact of Surgery Extent on Survival and Recurrence Rate of

More information

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal Diseases of cervix I. Inflammations 1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal squamous mucosa

More information

Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis

Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis American Journal of Obstetrics and Gynecology (2005) 193, 1640 4 www.ajog.org Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis Gilbert P. Pellerin, MD, Michael A.

More information

Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women

Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following

More information

The International Federation of Gynecology and Obstetrics (FIGO) updated the staging

The International Federation of Gynecology and Obstetrics (FIGO) updated the staging Continuing Education Column Revised FIGO Staging System Hee Sug Ryu, MD Department of Obstetrics and Gynecology, Ajou University School of Medicine E - mail : hsryu@ajou.ac.kr J Korean Med Assoc 2010;

More information

Janjira Petsuksiri, M.D

Janjira Petsuksiri, M.D GYN malignancies Janjira Petsuksiri, M.D Outlines Cervical cancer Endometrial cancer Ovarian cancer Vaginal cancer Vulva cancer 2 CA Cervix Epidemiology - Second most common female cancer Risk factors

More information

Newton Wellesley Hospital 2013

Newton Wellesley Hospital 2013 Newton Wellesley Hospital 20 Standard 4.6 Assessment and Evaluation of Treatment Planning Endometrial Cancer Each year a physician member of the cancer committee conducts a study to ensure that diagnostic

More information

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive

More information

Pre-operative Evaluation and Implications

Pre-operative Evaluation and Implications Pre-operative Evaluation and Implications Michal Zikan Gynecologic Oncology Center Charles University in Prague, First Faculty of Medicine No recommendation for screening of EC (HNPCC annual biopsies starting

More information

Index. Cytoplasm, nonepithelial malignant tumor features 70

Index. Cytoplasm, nonepithelial malignant tumor features 70 Accurette device 23 Adenosarcoma, differential diagnosis 80, 81 Arias-Stella reaction 65 Atypical endocervical cells 8 Atypical endometrial cells 8 Atypical glandular cells (AGC) 8, 9 Atypical glandular

More information

MRI in Cervix and Endometrial Cancer

MRI in Cervix and Endometrial Cancer 28th Congress of the Hungarian Society of Radiologists RCR Session Budapest June 2016 MRI in Cervix and Endometrial Cancer DrSarah Swift St James s University Hospital Leeds, UK Objectives Cervix and endometrial

More information

Endometrial cancer. Cathrine Holland

Endometrial cancer. Cathrine Holland Endometrial cancer athrine Holland Abstract Endometrial cancers are the most common gynaecological malignancies in the UKwith approximately 4500 new cases occur each year and the incidence is rising. Increasingly

More information

Case 1. Gynaecology Case Presentation. Objectives. Disclosures 22/10/ year old female Clinical history: Assess right ovarian cyst

Case 1. Gynaecology Case Presentation. Objectives. Disclosures 22/10/ year old female Clinical history: Assess right ovarian cyst Gynaecology Case Presentation Organ Imaging 2016 University of Toronto Sarah Johnson 39 year old female Clinical history: Assess right ovarian cyst Clinically diagnosed endometriosis Started fertility

More information

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE Case: Adenosarcoma with heterologous elements and stromal overgrowth o TAH, BSO, omentectomy, staging biopsies of cul-de-sac, bladder

More information

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells 2013 California Society of Pathologists 66 th Annual Meeting San Francisco, CA Atypical Glandular Cells to Early Invasive Adenocarcinoma: Cervical Cytology and Histology Christina S. Kong, MD Associate

More information

JMSCR Vol 05 Issue 11 Page November 2017

JMSCR Vol 05 Issue 11 Page November 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.78 A Histomorphological Study of Carcinoma

More information

Case Scenario 1. History

Case Scenario 1. History History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family

More information

Endometrial adenocarcinoma icd 10 code

Endometrial adenocarcinoma icd 10 code Endometrial adenocarcinoma icd 10 code Gogamz Menu Cancer of the endometrium, adenocarcinoma ;. (mucous membrane that lines the endometrial cavity). ICD - 10 -CM C54.1 is grouped within. ICD-10 -CM Diagnosis

More information

29 Cancer of the Uterine Corpus

29 Cancer of the Uterine Corpus 29 Cancer of the Uterine Corpus Robbert Soeters INTRODUCTION Malignancies affecting the uterine corpus are endometrial adenocarcinoma and uterine sarcomas. ENDOMETRIAL ADENOCARCINOMA Endometrial adenocarcinoma

More information

Gynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer

Gynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy

More information

ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป

ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป Brachytherapy การร กษาด วยร งส ระยะใกล Insertion การสอดใส แร Implantation การฝ งแร Surface application การวางแร physical benefit of brachytherapy - very high dose of radiation

More information

STUMPed for a Diagnosis Contemporary Management of Uterine Sarcomas

STUMPed for a Diagnosis Contemporary Management of Uterine Sarcomas UCSF Helen Diller Family Comprehensive Cancer Center Disclosures I have no financial disclosures STUMPed for a Diagnosis Contemporary Management of Uterine Sarcomas Lee-may Chen, MD Department of Obstetrics,

More information

Current staging of endometrial carcinoma with MR imaging

Current staging of endometrial carcinoma with MR imaging Current staging of endometrial carcinoma with MR imaging Poster No.: C-1436 Congress: ECR 2015 Type: Educational Exhibit Authors: M. Magalhaes, H. Donato, C. B. Marques, P. Gomes, F. Caseiro Alves; Coimbra/PT

More information

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT QUESTION #1 WHICH OF THE FOLLOWING IS NOT A RISK FACTOR FOR CERVICAL CANCER? A. HIGH RISK HPV B. CIGARETTE SMOKING C.

More information

Received, June 29, 1904; accepted for publication

Received, June 29, 1904; accepted for publication THE AMEBICAN JOURNAL OF CLINICAL PATHOLOGY Copyright 1964 by The Williams & Wilkins Co. Vol. 42, No. 0 Printed in U.S.A. CARCINOMA IN SITU OF THE ENDOMETRIUM ISABELLE A. BUEHL, M.D., PRANK VELLIOS, M.D.,

More information

Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center

Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center 50 yo healthy postmenopausal female with BMI = 35 with screening PAP smear = AGUS. What is the next step? (1) Colposcopy

More information

Shina Oranratanaphan, Tarinee Manchana*, Nakarin Sirisabya

Shina Oranratanaphan, Tarinee Manchana*, Nakarin Sirisabya Comparison of Synchronous Endometrial and Ovarian Cancers versus Primary with Metastasis RESEARCH COMMUNICATION Clinicopathologic Variables and Survival Comparison of Patients with Synchronous Endometrial

More information

Can the Ovaries be preserved in Selected Cases of Endometrial Cancer?

Can the Ovaries be preserved in Selected Cases of Endometrial Cancer? Can the Ovaries be preserved in Selected Cases of Endometrial Cancer? Parekh C D 1*, Desai A D 2, Patel B M 3, Patel S M 4, Mankad M H 5 1 Assistant Professor,Department of Gynaecologic Oncology, Gujarat

More information

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April

More information

Hitting the High Points Gynecologic Oncology Review

Hitting the High Points Gynecologic Oncology Review Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and

More information

Endometrial line thickness in different conditions.

Endometrial line thickness in different conditions. Endometrial line thickness in different conditions 1 Endometrial thickens in response to Rising estrogen levels during the menstrual cycle and then shedding endometrial at the times of menses 2 The thickens

More information

RETROSPECTIVE RECORD REVIEW OF PATIENTS DIAGNOSED WITH ENDOMETRIAL CANCER AND CARCINOSARCOMA AT RAHIMA

RETROSPECTIVE RECORD REVIEW OF PATIENTS DIAGNOSED WITH ENDOMETRIAL CANCER AND CARCINOSARCOMA AT RAHIMA RETROSPECTIVE RECORD REVIEW OF PATIENTS DIAGNOSED WITH ENDOMETRIAL CANCER AND CARCINOSARCOMA AT RAHIMA MOOSA MOTHER AND CHILD HOSPITAL RECEIVING TREATMENT AT CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC HOSPITAL

More information

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms

More information

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan Female Genital Tract Lab Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan Ovarian Pathology A 20-year-old female presented with vague left pelvic pain. Pelvic exam revealed

More information

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review

More information

5 Mousa Al-Abbadi. Ola Al-juneidi & Obada Zalat. Ahmad Al-Tarefe

5 Mousa Al-Abbadi. Ola Al-juneidi & Obada Zalat. Ahmad Al-Tarefe 5 Mousa Al-Abbadi Ola Al-juneidi & Obada Zalat Ahmad Al-Tarefe Abnormal Uterine Bleeding (AUB) AUB is a very common scenario or symptom where women complain of menorrhagia (heavy and/or for long periods),

More information

Gynecological Cancers

Gynecological Cancers Gynecological Cancers Outline Ovarian Cancer Uterine (Endometrial) Cancer Cervical Cancer Vulvar Cancer Vaginal Cancer Overian Cancer Ovarian cancer is cancer that forms in the tissue of the ovary and

More information

The Primary Squamous Cell Carcinoma of The Endometrium: A Case Report and Literature Review

The Primary Squamous Cell Carcinoma of The Endometrium: A Case Report and Literature Review May, 2018 2018; Vol2; Issue5 http://iamresearcher.online The Primary Squamous Cell Carcinoma of The Endometrium: A Case Report and Literature Review Ahmed Guennoun, Yousra Krimou, Chahrazad Bouchikhi,

More information

64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus

64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus Case 6 64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus Numerous irregular, large glands with leaf-like pattern Large glands with broad-based papillary infolding into the

More information

Updates in Gynecologic Oncology. Todd Boren, MD Gynecologic Oncologist Chattanooga s Program in Women s Oncology Sept 8 th, 2018

Updates in Gynecologic Oncology. Todd Boren, MD Gynecologic Oncologist Chattanooga s Program in Women s Oncology Sept 8 th, 2018 Updates in Gynecologic Oncology Todd Boren, MD Gynecologic Oncologist Chattanooga s Program in Women s Oncology Sept 8 th, 2018 COI I have no conflict of interest to report Endometrial Cancer: Risk Factors

More information

TOC NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence,

More information

Gynaecology NSSG (Lancs & South Cumbria) Uterine Cancer Guidelines (V4.0)

Gynaecology NSSG (Lancs & South Cumbria) Uterine Cancer Guidelines (V4.0) Gynaecology NSSG (Lancs & South Cumbria) Uterine Cancer Guidelines (V4.0) ** VALID ON DATE OF PRINTING ONLY all guidelines available on the Strategic Clinical Network website : GMLSC SCN Date first published

More information

HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE PERIOD

HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE PERIOD HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE 2000-2009 PERIOD Gheorghe Furău 1), Voicu Daşcău 1), Cristian Furău 1), Lucian

More information

A Rare Case of Invasive Squamous Cell Carcinoma of Cervix Extending to Endometrium and Right Fallopian Tube

A Rare Case of Invasive Squamous Cell Carcinoma of Cervix Extending to Endometrium and Right Fallopian Tube A Rare Case of Invasive Squamous Cell Carcinoma of Cervix Extending to Endometrium and Right Fallopian Tube Kate Madhuri S 1, Gulhane Sushma R 2, Mane Sheetal V 3 1 Professor and Head, 2 Specialist cum

More information

Contemporary Issues in the Management of Endometrial Cancer

Contemporary Issues in the Management of Endometrial Cancer C A C a n c e r J C l i n 1 9 9 8 ; 4 8 : 2 9 9-3 1 4 Contemporary Issues in the Management of Endometrial Cancer Richard R. Barakat, MD Cancer of the epithelial lining (endometrium) of the uterine corpus

More information

Uterus Malignancies /5/15

Uterus Malignancies /5/15 Collecting Cancer Data: Uterus 2014-2015 NAACCR Webinar Series February 5, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

Endosalpingiosis. Case report

Endosalpingiosis. Case report Case report Endosalpingiosis Michael D. Holmes, M.D. Howard S. Levin M.D. Department of Pathology Lester A. Ballard, Jr., M.D. Department of Gynecology Endosalpingiosis, a term referring to tuballike epithelium

More information

CPC on Cervical Pathology

CPC on Cervical Pathology CPC on Cervical Pathology Dr. W.K. Ng Senior Medical Officer Department of Clinical Pathology Pamela Youde Nethersole Eastern Hospital Cervical Smear: High Grade SIL (CIN III) Cervical Smear: High Grade

More information

uterine cancer endometrial cancer

uterine cancer endometrial cancer 2018 ICD-10-CM Diagnosis Code. Adenocarcinoma of endometrium ; Cancer of the. (mucous membrane that lines the endometrial cavity). ICD-10-CM C54.1 is grouped. Home ICD 9 Codes Endometrial Cancer ICD 9

More information

Coversheet for Network Site Specific Group Agreed Documentation

Coversheet for Network Site Specific Group Agreed Documentation Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance

More information

Demystifying Endometrial Hyperplasia

Demystifying Endometrial Hyperplasia Demystifying Endometrial Hyperplasia A review from Diagnostic Histopathology 19:7 Dr R Hadden ST5 Histopathology Derriford Hospital Plymouth Endometrium Target for sex-steroid hormones Glands Stroma Proliferate

More information

Endometrial cancer. Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology.

Endometrial cancer. Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology. Endometrial cancer Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology dr.mate.szabolcs@gmail.com Epidemiology Developing countries Cervical cancer is the most common gyn. malignant tumor

More information

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized

More information